Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Vaccination With RA 27/3 Rubella Vaccine

Vaccination With RA 27/3 Rubella Vaccine Abstract In order to further establish the safety of RA 27/3 vaccine and the quality of its antigenic response, both subcutaneous and intranasal administration of vaccine were studied. A contact study carried out in 70 families proved RA 27/3 vaccine to be noncontagious. The antibody response (hemagglutination-inhibition test) following vaccination, checked in 387 seronegative individuals, was only slightly inferior to that in individuals with preexisting naturally acquired antibodies. In children the failure rate was 7% when vaccine was administered intranasally and 0% when given subcutaneously. In adults, who were vaccinated only subcutaneously, 4% did not develop seroconversion. After three years, decline of the level of vaccine-induced antibodies was slightly faster than that of naturally immune individuals. In no instance was there loss of a significant titer. Negligible side reactions consisted in a few cases of slight indolent swellings of the nuchal glands. Rarely was a faint transient rash noted. No individual developed arthralgia or arthritis. References 1. Plotkin SA, Cornfeld D, Ingalls TH: Studies of immunization with living rubella virus . Amer J Dis Child 110:381-389, 1965.Crossref 2. Plotkin SA, Farquhar JD, Katz M, et al: A new attenuated rubella virus grown in human fibroblasts: Evidence for reduced nasopharyngeal excretion . Amer J Epidem 86:468-477, 1967. 3. Plotkin SA, Ingalls TH, Farquhar JD, et al: Intranasally administered rubella vaccine . Lancet 2:934-937, 1968.Crossref 4. Plotkin SA, Farquhar JD, Katz M, et al: Further studies of an attenuated rubella strain grown in WI-38 cells . Amer J Epidem 89:232-238, 1969. 5. Plotkin SA: Development of RA 27/3 attenuated rubella virus grown in WI-38 cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 249-260. 6. Plotkin SA, Katz M, Farquhar JD, et al: Clinical trials of RA 27/3 attenuated rubella virus grown in WI-38 cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 373-386. 7. Buser F, Nicolas A, Plotkin SA: Vaccination with the RA 27/3 strain of attenuated rubella virus grown in human diploid cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 391-396. 8. Plotkin SA, Farquhar JD, Katz M, et al: Attenuation of RA 27/3 rubella virus in WI-38 human diploid cells . Amer J Dis Child 118:178-185, 1969. 9. Stewart GL, Parkman PD, Hopps HE, et al: Rubella virus hemagglutination-inhibition test . New Eng J Med 276:554-557, 1967.Crossref 10. Nicolas A: Méthodes de laboratoire appliquées au diagnostic de la rubéole: La technique d'inhibition de l'hémagglutination . Lyon Med 27:17-52, 1967. 11. Boué A, Nicolas A, Lang R: La réaction d'inhibition de l'hémagglutination pour la sérologie de la rubéole . Ann Inst Pasteur 114:317-330, 1968. 12. Monnet P, Nicolas A, Lang R: Vaccination antirubéoleuse avec la souche Plotkin . Presse Med 78:107, 1970. 13. Dudgeon JA, Marshall WC, Peckham CS: Rubella vaccine trials in adults and children . Amer J Dis Child 118:237-242, 1969.Crossref 14. Wilkins J, Leedom JM, Portnoy B, et al: Reinfection with rubella virus despite live vaccine induced immunity . Amer J Dis Child 118:275-294, 1969.Crossref 15. Detels R, Grayston JT, Kim KSW, et al: Prevention of clinical and subclinical rubella infection . Amer J Dis Child 118:295-300, 1969.Crossref 16. Chang T, DesRosiers S, Weinstein L: Clinical and serologic studies of an outbreak of rubella in a vaccinated population . New Eng J Med 283:246-248, 1970.Crossref 17. Horstmann DM, Liebhaber H, Le Bouvier GL, et al: Rubella: Reinfection of vaccinated and naturally immune persons exposed in an epidemic . New Eng J Med 283:771-778, 1970.Crossref 18. Svedmyr A: Acquisition and decline of rubella immunity . Amer J Dis Child 118:137-138, 1969.Crossref 19. Andzhaparidze OG, Desyatskova RG, Chervonski GI, et al: Immunogenicity and reactogenicity of live attenuated rubella virus vaccines . Amer J Epidem 91:527-530, 1970. 20. Fogel A, Moshkowitz A, Rannon L, et al: Comparative trials of RA 27/3 and Cendehill rubella vaccines in adult and adolescent females. Amer J Epidem, to be published. 21. Hilleman MR, Buynak EB, Whitman JE Jr, et al: Live attenuated rubella virus vaccine . Amer J Dis Child 118:166-171, 1969.Crossref 22. Karchmer AW, Herrmann KL, Friedman JP, et al: Comparative studies of rubella vaccines . Amer J Dis Child 118:196-202, 1969. 23. Cooper LZ, Ziring PR, Weiss HJ, et al: Transient arthritis after rubella vaccination . Amer J Dis Child 118:218-225, 1969.Crossref 24. Weibel RE, Stokes J Jr, Buynak EB, et al: Live rubella vaccines in adults and children . Amer J Dis Child 118:226-229, 1969.Crossref 25. Byrne EB, Ryan JM, Randolph MF, et al: Live attenuated rubella virus vaccines in young adult women . Amer J Dis Child 118:234-236, 1969.Crossref 26. Furukawa T, Miyata T, Kondo K, et al: Clinical trials of RA 27/3 (Wistar) rubella vaccine in Japan . Amer J Dis Child 118:262-263, 1969. 27. Naficy K, Nategh R, Khakpour: Efficacy of subcutaneous and intranasal administration of RA 27/3 rubella vaccine , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 405-410. 28. Moshkowitz A, Nishmi M, Fogel A, et al: Preliminary trials with rubella vaccines , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 443-444. 29. Hayflick L, Plotkin SA, Norton TW, et al: Preparation of poliovirus vaccines in a human fetal diploid cell strain . Amer J Hyg 75:240-258, 1962. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Diseases of Children American Medical Association

Vaccination With RA 27/3 Rubella Vaccine

Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/vaccination-with-ra-27-3-rubella-vaccine-YjmkNTnAMi

References (35)

Publisher
American Medical Association
Copyright
Copyright © 1971 American Medical Association. All Rights Reserved.
ISSN
0002-922X
DOI
10.1001/archpedi.1971.02110010089015
Publisher site
See Article on Publisher Site

Abstract

Abstract In order to further establish the safety of RA 27/3 vaccine and the quality of its antigenic response, both subcutaneous and intranasal administration of vaccine were studied. A contact study carried out in 70 families proved RA 27/3 vaccine to be noncontagious. The antibody response (hemagglutination-inhibition test) following vaccination, checked in 387 seronegative individuals, was only slightly inferior to that in individuals with preexisting naturally acquired antibodies. In children the failure rate was 7% when vaccine was administered intranasally and 0% when given subcutaneously. In adults, who were vaccinated only subcutaneously, 4% did not develop seroconversion. After three years, decline of the level of vaccine-induced antibodies was slightly faster than that of naturally immune individuals. In no instance was there loss of a significant titer. Negligible side reactions consisted in a few cases of slight indolent swellings of the nuchal glands. Rarely was a faint transient rash noted. No individual developed arthralgia or arthritis. References 1. Plotkin SA, Cornfeld D, Ingalls TH: Studies of immunization with living rubella virus . Amer J Dis Child 110:381-389, 1965.Crossref 2. Plotkin SA, Farquhar JD, Katz M, et al: A new attenuated rubella virus grown in human fibroblasts: Evidence for reduced nasopharyngeal excretion . Amer J Epidem 86:468-477, 1967. 3. Plotkin SA, Ingalls TH, Farquhar JD, et al: Intranasally administered rubella vaccine . Lancet 2:934-937, 1968.Crossref 4. Plotkin SA, Farquhar JD, Katz M, et al: Further studies of an attenuated rubella strain grown in WI-38 cells . Amer J Epidem 89:232-238, 1969. 5. Plotkin SA: Development of RA 27/3 attenuated rubella virus grown in WI-38 cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 249-260. 6. Plotkin SA, Katz M, Farquhar JD, et al: Clinical trials of RA 27/3 attenuated rubella virus grown in WI-38 cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 373-386. 7. Buser F, Nicolas A, Plotkin SA: Vaccination with the RA 27/3 strain of attenuated rubella virus grown in human diploid cells , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 391-396. 8. Plotkin SA, Farquhar JD, Katz M, et al: Attenuation of RA 27/3 rubella virus in WI-38 human diploid cells . Amer J Dis Child 118:178-185, 1969. 9. Stewart GL, Parkman PD, Hopps HE, et al: Rubella virus hemagglutination-inhibition test . New Eng J Med 276:554-557, 1967.Crossref 10. Nicolas A: Méthodes de laboratoire appliquées au diagnostic de la rubéole: La technique d'inhibition de l'hémagglutination . Lyon Med 27:17-52, 1967. 11. Boué A, Nicolas A, Lang R: La réaction d'inhibition de l'hémagglutination pour la sérologie de la rubéole . Ann Inst Pasteur 114:317-330, 1968. 12. Monnet P, Nicolas A, Lang R: Vaccination antirubéoleuse avec la souche Plotkin . Presse Med 78:107, 1970. 13. Dudgeon JA, Marshall WC, Peckham CS: Rubella vaccine trials in adults and children . Amer J Dis Child 118:237-242, 1969.Crossref 14. Wilkins J, Leedom JM, Portnoy B, et al: Reinfection with rubella virus despite live vaccine induced immunity . Amer J Dis Child 118:275-294, 1969.Crossref 15. Detels R, Grayston JT, Kim KSW, et al: Prevention of clinical and subclinical rubella infection . Amer J Dis Child 118:295-300, 1969.Crossref 16. Chang T, DesRosiers S, Weinstein L: Clinical and serologic studies of an outbreak of rubella in a vaccinated population . New Eng J Med 283:246-248, 1970.Crossref 17. Horstmann DM, Liebhaber H, Le Bouvier GL, et al: Rubella: Reinfection of vaccinated and naturally immune persons exposed in an epidemic . New Eng J Med 283:771-778, 1970.Crossref 18. Svedmyr A: Acquisition and decline of rubella immunity . Amer J Dis Child 118:137-138, 1969.Crossref 19. Andzhaparidze OG, Desyatskova RG, Chervonski GI, et al: Immunogenicity and reactogenicity of live attenuated rubella virus vaccines . Amer J Epidem 91:527-530, 1970. 20. Fogel A, Moshkowitz A, Rannon L, et al: Comparative trials of RA 27/3 and Cendehill rubella vaccines in adult and adolescent females. Amer J Epidem, to be published. 21. Hilleman MR, Buynak EB, Whitman JE Jr, et al: Live attenuated rubella virus vaccine . Amer J Dis Child 118:166-171, 1969.Crossref 22. Karchmer AW, Herrmann KL, Friedman JP, et al: Comparative studies of rubella vaccines . Amer J Dis Child 118:196-202, 1969. 23. Cooper LZ, Ziring PR, Weiss HJ, et al: Transient arthritis after rubella vaccination . Amer J Dis Child 118:218-225, 1969.Crossref 24. Weibel RE, Stokes J Jr, Buynak EB, et al: Live rubella vaccines in adults and children . Amer J Dis Child 118:226-229, 1969.Crossref 25. Byrne EB, Ryan JM, Randolph MF, et al: Live attenuated rubella virus vaccines in young adult women . Amer J Dis Child 118:234-236, 1969.Crossref 26. Furukawa T, Miyata T, Kondo K, et al: Clinical trials of RA 27/3 (Wistar) rubella vaccine in Japan . Amer J Dis Child 118:262-263, 1969. 27. Naficy K, Nategh R, Khakpour: Efficacy of subcutaneous and intranasal administration of RA 27/3 rubella vaccine , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 405-410. 28. Moshkowitz A, Nishmi M, Fogel A, et al: Preliminary trials with rubella vaccines , in International Symposium on Rubella Vaccines, London 1968: Series Immunobiological Standard . New York, S Karger AG, 1969, vol 11, pp 443-444. 29. Hayflick L, Plotkin SA, Norton TW, et al: Preparation of poliovirus vaccines in a human fetal diploid cell strain . Amer J Hyg 75:240-258, 1962.

Journal

American Journal of Diseases of Children – American Medical Association

Published: Jul 1, 1971

There are no references for this article.